A new hope in cachexia and an outsider’s view on pharma: the pharmaphorum podcast

In the latest instalment of the pharmaphorum podcast, Editor in Chief Jonah Comstock sits down with Russell Potterfield, CEO at Endevica Pharma. A biotech CEO who comes from the business and investment worlds, Russell now runs Endevica, which is working on a novel therapy for cachexia, a wasting syndrome that accompanies many cancers. Russell talks a bit about his company’s unconventional approach to this common cancer comorbidity, but also talks about his experience as an outsider coming into the complex biotech world, and discusses the factors that go into how a biotech thinks about decisions about licensing and commercialisation. Tune in for a new view of the pharma world and a deep dive into an oft-overlooked condition. You can listen to episode 66 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the rest of the series in iTunes, Spotify, acast, Stitcher, and Podbean.